Clinical Trial

Trial Protocol ID USOR 22107_CA116-003

Trial Description

A Phase 2, Open-Label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Vinni Juneja, M.D.

Disease Types

Sponsor

  • BRISTOL-MYERS SQUIBB

ClinicalTrials.gov NCT ID

  • NCT05577715